Scientists test Double-Punch cancer vaccine to boost CAR-T power
NCT ID NCT07377435
Summary
This early-phase study is testing whether adding a personalized cancer vaccine can make a powerful cell therapy (CAR-T) work better for people with multiple myeloma that has come back or stopped responding to other treatments. The vaccine is made from a patient's own immune cells fused with their cancer cells, aiming to teach the immune system to better recognize and attack the cancer. The main goal is to see if this combination is safe and tolerable for about 25 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.